New vaccine, long-acting drug trials buoy hopes in HIV fight
Researchers announced the launch of two big studies in Africa on Thursday to test a new HIV vaccine and a long-acting injectable drug, fuelling hopes for better ways to protect against the virus that causes AIDS.
The start of the three-year vaccine trial involving 2,600 women in southern Africa means that for the first time in more than a decade there are now two big HIV vaccine clinical trials taking place at the same time.
The new study is testing a two-vaccine combination developed by Johnson & Johnson (J&J) with the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation. The first vaccine, also backed by NIH, began a trial last November.